Cerulean Pharma Company Profile (NASDAQ:CERU)

About Cerulean Pharma (NASDAQ:CERU)

Cerulean Pharma logoCerulean Pharma Inc. is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads. Its NDC platform is designed to create NDCs that accumulate high concentrations of active drug in tumor cells, without exposure to healthy tissue. Its platform is applicable to a range of payloads. It has created NDCs with a range of small molecule payloads, including Jevtana (cabazitaxel), gemcitabine, methotrexate and Xeljanz (tofacitinib). The Company's product pipeline consists of CRLX101 and CRLX301. Its CRLX101 is a tumor targeted NDC. Its CRLX301 has docetaxel as its anti-cancer payload. CRLX101 has a camptothecin payload, which is a topoisomerase 1 (topo 1) inhibitor. CRLX301 is designed to concentrate docetaxel in tumor cells and spare healthy tissue.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CERU
  • CUSIP: N/A
  • Web: www.ceruleanrx.com
Capitalization:
  • Market Cap: $11.56 million
  • Outstanding Shares: 29,021,000
Average Prices:
  • 50 Day Moving Avg: $0.52
  • 200 Day Moving Avg: $0.90
  • 52 Week Range: $0.33 - $3.58
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.64
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $1.96 million
  • Price / Sales: 5.90
  • Book Value: $0.27 per share
  • Price / Book: 1.49
Profitability:
  • EBIDTA: ($31,050,000.00)
  • Return on Equity: -141.78%
  • Return on Assets: -77.97%
Debt:
  • Debt-to-Equity Ratio: 0.39%
  • Current Ratio: 2.47%
  • Quick Ratio: 2.47%
Misc:
  • Average Volume: 3.28 million shs.
  • Beta: 2.07
  • Short Ratio: 0.38
 

Frequently Asked Questions for Cerulean Pharma (NASDAQ:CERU)

What is Cerulean Pharma's stock symbol?

Cerulean Pharma trades on the NASDAQ under the ticker symbol "CERU."

How were Cerulean Pharma's earnings last quarter?

Cerulean Pharma Inc (NASDAQ:CERU) announced its quarterly earnings data on Thursday, August, 4th. The company reported ($0.40) EPS for the quarter, topping the Zacks' consensus estimate of ($0.48) by $0.08. View Cerulean Pharma's Earnings History.

Where is Cerulean Pharma's stock going? Where will Cerulean Pharma's stock price be in 2017?

6 brokers have issued 1-year price targets for Cerulean Pharma's shares. Their predictions range from $1.50 to $6.00. On average, they expect Cerulean Pharma's share price to reach $3.00 in the next twelve months. View Analyst Ratings for Cerulean Pharma.

Are investors shorting Cerulean Pharma?

Cerulean Pharma saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 2,728,058 shares, an increase of 14.9% from the April 13th total of 2,374,061 shares. Based on an average trading volume of 630,298 shares, the short-interest ratio is presently 4.3 days.

Who are some of Cerulean Pharma's key competitors?

Who owns Cerulean Pharma stock?

Cerulean Pharma's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Polaris Venture Management Co. V L.L.C. (11.33%), Vanguard Group Inc. (3.10%) and KCG Holdings Inc. (2.69%). View Institutional Ownership Trends for Cerulean Pharma.

Who bought Cerulean Pharma stock? Who is buying Cerulean Pharma stock?

Cerulean Pharma's stock was bought by a variety of institutional investors in the last quarter, including KCG Holdings Inc. and Vanguard Group Inc.. View Insider Buying and Selling for Cerulean Pharma.

How do I buy Cerulean Pharma stock?

Shares of Cerulean Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cerulean Pharma stock cost?

One share of Cerulean Pharma stock can currently be purchased for approximately $0.40.

Analyst Ratings

Consensus Ratings for Cerulean Pharma (NASDAQ:CERU) (?)
Ratings Breakdown: 3 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.00 (652.82% upside)

Analysts' Ratings History for Cerulean Pharma (NASDAQ:CERU)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/9/2016Canaccord GenuityReiterated RatingBuy$6.00N/AView Rating Details
10/23/2016Roth CapitalReiterated RatingBuy$2.50N/AView Rating Details
10/19/2016Leerink SwannReiterated RatingMarket Perform$1.50N/AView Rating Details
8/30/2016Barclays PLCLower Price TargetOverweight$5.00 -> $2.00N/AView Rating Details
8/18/2016WedbushDowngradeOutperform -> NeutralN/AView Rating Details
8/18/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
3/9/2016JPMorgan Chase & Co.Boost Price TargetMarket Outperform$9.00 -> $16.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $9.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Cerulean Pharma (NASDAQ:CERU)
Earnings by Quarter for Cerulean Pharma (NASDAQ:CERU)
Earnings History by Quarter for Cerulean Pharma (NASDAQ:CERU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/4/2016Q216($0.48)($0.40)ViewN/AView Earnings Details
5/2/2016Q116($0.43)($0.49)ViewN/AView Earnings Details
3/10/2016Q415($0.41)($0.39)ViewListenView Earnings Details
11/16/2015Q315($0.41)($0.39)ViewListenView Earnings Details
8/6/2015Q215($0.40)($0.37)ViewN/AView Earnings Details
3/19/2015Q4 2014($0.36)($0.37)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.32)($0.28)ViewN/AView Earnings Details
8/12/2014Q2 2014($0.36)($0.34)$0.03 millionViewN/AView Earnings Details
5/27/2014Q1 2014($3.52)($3.70)$0.05 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cerulean Pharma (NASDAQ:CERU)
2017 EPS Consensus Estimate: ($1.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.40)($0.40)($0.40)
Q2 20171($0.40)($0.40)($0.40)
Q3 20171($0.41)($0.41)($0.41)
Q4 20171($0.15)($0.15)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cerulean Pharma (NASDAQ:CERU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cerulean Pharma (NASDAQ:CERU)
Insider Ownership Percentage: 28.60%
Institutional Ownership Percentage: 22.90%
Insider Trades by Quarter for Cerulean Pharma (NASDAQ:CERU)
Institutional Ownership by Quarter for Cerulean Pharma (NASDAQ:CERU)
Insider Trades by Quarter for Cerulean Pharma (NASDAQ:CERU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2016David R WaltDirectorBuy2,291$2.08$4,765.28View SEC Filing  
2/18/2016David R. WaltDirectorBuy8,960$2.10$18,816.00View SEC Filing  
2/16/2016David R. WaltDirectorBuy8,811$2.00$17,622.00View SEC Filing  
2/11/2016David R. WaltDirectorBuy8,850$2.05$18,142.50View SEC Filing  
2/9/2016David R. WaltDirectorBuy9,000$2.15$19,350.00View SEC Filing  
2/5/2016David R. WaltDirectorBuy8,563$2.30$19,694.90View SEC Filing  
2/3/2016David R. WaltDirectorBuy8,413$2.32$19,518.16View SEC Filing  
2/1/2016David R. WaltDirectorBuy5,700$2.38$13,566.00View SEC Filing  
1/28/2016David R. WaltDirectorBuy9,000$2.46$22,140.00View SEC Filing  
1/26/2016David R. WaltDirectorBuy8,800$2.39$21,032.00View SEC Filing  
1/25/2016David R. WaltDirectorBuy4,500$2.35$10,575.00View SEC Filing  
1/22/2016David R. WaltDirectorBuy9,000$2.28$20,520.00View SEC Filing  
1/20/2016David R. WaltDirectorBuy8,900$2.43$21,627.00View SEC Filing  
1/15/2016David R. WaltDirectorBuy8,572$2.53$21,687.16View SEC Filing  
1/13/2016David R. WaltDirectorBuy8,684$2.79$24,228.36View SEC Filing  
1/11/2016David R. WaltDirectorBuy8,855$2.87$25,413.85View SEC Filing  
1/7/2016David R. WaltDirectorBuy8,800$2.95$25,960.00View SEC Filing  
1/5/2016David R. WaltDirectorBuy8,801$3.03$26,667.03View SEC Filing  
11/30/2015David R WaltDirectorBuy5,374$3.25$17,465.50View SEC Filing  
11/27/2015David R. WaltDirectorBuy12,117$3.32$40,228.44View SEC Filing  
4/7/2015Cvf, LlcMajor ShareholderBuy333,333$6.00$1,999,998.00View SEC Filing  
4/15/2014Alan L CraneDirectorBuy1,470,582$7.00$10,294,074.00View SEC Filing  
4/15/2014Eli & Co LillyMajor ShareholderBuy733,445$7.00$5,134,115.00View SEC Filing  
4/15/2014Lux Capital Management, LlcInsiderBuy106,224$7.00$743,568.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cerulean Pharma (NASDAQ:CERU)
Latest Headlines for Cerulean Pharma (NASDAQ:CERU)
Source:
DateHeadline
americanbankingnews.com logoCerulean Pharma Inc (CERU) Sees Significant Increase in Short Interest
www.americanbankingnews.com - May 16 at 7:18 AM
americanbankingnews.com logo Analysts Anticipate Cerulean Pharma Inc (CERU) Will Announce Earnings of -$0.31 Per Share
www.americanbankingnews.com - May 8 at 10:48 AM
finance.yahoo.com logoCerulean and Daré Announce Awards for Daré CEO
finance.yahoo.com - May 8 at 10:08 AM
prnewswire.com logoBiotech Stocks on Investors' Radar -- Array BioPharma, Celgene, Amgen, and Cerulean Pharma - PR Newswire (press release)
www.prnewswire.com - May 3 at 8:52 AM
americanbankingnews.com logoCerulean Pharma (CERU) Given Media Impact Score of 0.17
www.americanbankingnews.com - April 30 at 10:50 AM
americanbankingnews.com logoVery Favorable Press Coverage Extremely Likely to Affect Cerulean Pharma (CERU) Stock Price
www.americanbankingnews.com - April 26 at 12:48 PM
americanbankingnews.com logoCerulean Pharma (CERU) Earns Media Impact Rating of 0.14
www.americanbankingnews.com - April 23 at 2:57 PM
americanbankingnews.com logoVery Positive News Coverage Extremely Likely to Affect Cerulean Pharma (CERU) Stock Price
www.americanbankingnews.com - April 19 at 7:58 AM
News IconBRIEF-Cerulean Pharma estimates cash, cash equivalents as of June 30,
www.businessinsider.com - April 18 at 12:27 PM
americanbankingnews.com logoCerulean Pharma (CERU) Given Daily Media Impact Rating of 0.17
www.americanbankingnews.com - April 16 at 10:16 AM
americanbankingnews.com logoCerulean Pharma Inc (CERU) Short Interest Up 50.9% in March
www.americanbankingnews.com - April 15 at 7:44 AM
americanbankingnews.com logoCerulean Pharma Inc (CERU) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 7 at 8:55 PM
americanbankingnews.com logoCerulean Pharma Inc (CERU) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - April 4 at 6:10 PM
biz.yahoo.com logoCERULEAN PHARMA INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 31 at 4:24 PM
americanbankingnews.com logoCerulean Pharma Inc (CERU) to Release Quarterly Earnings on Friday
www.americanbankingnews.com - March 30 at 7:04 AM
biz.yahoo.com logoCERULEAN PHARMA INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 24 at 4:31 PM
bizjournals.com logoAs Cerulean Pharma winds down, executives get a parting gift: bonuses
www.bizjournals.com - March 21 at 4:32 PM
biz.yahoo.com logoCERULEAN PHARMA INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 21 at 4:32 PM
streetinsider.com logoCerulean Pharma (CERU), Dare Bioscience Enter Stock Purchase Agreement; Dare to Become Majority Owners
www.streetinsider.com - March 21 at 8:00 AM
rttnews.com logoCerulean Pharma Inc. (CERU) Sank To A 3-Week Low After Daré Bioscience Agreement
www.rttnews.com - March 21 at 8:00 AM
finance.yahoo.com logoCerulean and Daré to Host Conference Call on Proposed Transaction on March 23
finance.yahoo.com - March 21 at 8:00 AM
rttnews.com logoCerulean Pharma Inc. (CERU) Is Sinking After Daré Bioscience Agreement
www.rttnews.com - March 20 at 7:55 PM
reuters.com logoBRIEF-Cerulean Pharma and Daré Bioscience enter into stock purchase agreement
www.reuters.com - March 20 at 7:55 PM
us.rd.yahoo.com logoCerulean Pharma and Daré Bioscience Enter into Stock Purchase Agreement
us.rd.yahoo.com - March 20 at 7:55 PM
us.rd.yahoo.com logo8:02 am Cerulean Pharma announces Dare Bioscience will become a majority owner of Cerulean; sells CRLX101 & CRLX301 for $1.5 mln to BlueLink Pharma and its rights to its Dynamic Tumor Targeting Platform for $6 mln to Novartis (nasdaq.com logoMid-Day Market Update: Nektar Surges After Positive Results From NKTR-181 Study; Cerulean Pharma Shares Drop - Nasdaq
www.nasdaq.com - March 20 at 2:54 PM
biz.yahoo.com logoCERULEAN PHARMA INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defini
biz.yahoo.com - March 20 at 2:54 PM
bizjournals.com logoWaltham's Cerulean Pharma to cut staff, merge with San Diego biotech
www.bizjournals.com - March 20 at 2:54 PM
finanznachrichten.de logoGainers & Losers Of Mar.15: CERU, CPRX, ARNA, AKAO, GNCA...
www.finanznachrichten.de - March 16 at 2:40 AM
rttnews.com logoCerulean Pharma Inc. (CERU) Has Surged To Nearly A 7-Month High
www.rttnews.com - March 13 at 12:43 PM
americanbankingnews.com logoCerulean Pharma Inc (CERU) Receives Average Recommendation of “Buy” from Brokerages
www.americanbankingnews.com - March 8 at 3:49 PM
streetinsider.com logoCerulean Pharma (CERU) to Review of Strategic Alternatives - StreetInsider.com
www.streetinsider.com - February 2 at 4:29 PM
streetinsider.com logoCerulean Pharma (CERU) to Review of Strategic Alternatives
www.streetinsider.com - February 1 at 9:34 PM
reuters.com logoBRIEF-Cerulean announces review of strategic alternatives
www.reuters.com - February 1 at 4:29 PM
finance.yahoo.com logoCerulean Announces Review of Strategic Alternatives
finance.yahoo.com - February 1 at 4:29 PM
finance.yahoo.com logo8:01 am Cerulean Pharma announces that its Board is conducting a comprehensive review of strategic alternatives (shares halted)
finance.yahoo.com - February 1 at 4:29 PM
bizjournals.com logoWaltham-based cancer drug firm Cerulean Pharma may seek a buyer
www.bizjournals.com - February 1 at 4:29 PM

Social

Chart

Cerulean Pharma (CERU) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff